Research Analysts’ Weekly Ratings Changes for Intercept Pharmaceuticals (ICPT)

A number of firms have modified their ratings and price targets on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) recently:

  • 2/13/2018 – Intercept Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $57.00 price target on the stock, down previously from $62.00.
  • 2/12/2018 – Intercept Pharmaceuticals is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $103.00 price target on the stock.
  • 2/7/2018 – Intercept Pharmaceuticals was downgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “sell” rating.
  • 2/2/2018 – Intercept Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 1/29/2018 – Intercept Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 1/25/2018 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $253.00 price target on the stock, down previously from $332.00.
  • 1/25/2018 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/22/2018 – Intercept Pharmaceuticals was given a new $167.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 1/16/2018 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/16/2018 – Intercept Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “The approval of Ocaliva was a significant boost for Intercept. Intercept is evaluating Ocaliva for other indications including NASH and PSC. A label expansion of the drug will bode well. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. Recently, some deaths have been reported in PBC patients with moderate or severe hepatic impairment (Child Pugh B or C cirrhosis). However, Intercept conducted an analysis and concluded that these patients were prescribed once daily doses of Ocaliva, which is seven times higher than the recommended weekly dose. The company concluded that deaths occurred due to overdosing. Consequently, Intercept issued the Dear Healthcare Provider letter. Thereafter, the FDA issued their own safety communication to reinforce recommended label dosing. Shares have underperformed the industry in the last six months.”
  • 1/9/2018 – Intercept Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Intercept is facing challenges with its lead drug Ocaliva. Prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. Recently, some deaths have been reported in PBC patients with moderate or severe hepatic impairment (Child Pugh B or C cirrhosis). However, Intercept conducted an analysis and concluded that these patients were prescribed once daily doses of Ocaliva, which is seven times higher than the recommended weekly dose. The company concluded that deaths occurred due to overdosing. Consequently, Intercept issued the Dear Healthcare Provider letter. Thereafter, the FDA issued their own safety communication to reinforce recommended label dosing. Shares have underperformed the industry in the last six months. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC.A label expansion will bode well.”
  • 1/5/2018 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $253.00 price target on the stock.
  • 12/29/2017 – Intercept Pharmaceuticals was given a new $74.00 price target on by analysts at Citigroup Inc. They now have a “hold” rating on the stock.
  • 12/22/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $253.00 price target on the stock.
  • 12/21/2017 – Intercept Pharmaceuticals was given a new $74.00 price target on by analysts at Citigroup Inc. They now have a “hold” rating on the stock.

Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) traded up $0.42 during mid-day trading on Tuesday, reaching $54.63. 1,022,500 shares of the company’s stock were exchanged, compared to its average volume of 1,078,449. The company has a market cap of $1,360.78, a price-to-earnings ratio of -3.69 and a beta of -2.13. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals Inc has a fifty-two week low of $51.05 and a fifty-two week high of $135.59.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply